Extent of macroscopic vascular invasion predicts distant metastasis in primary leiomyosarcoma of the inferior vena cava
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von William W Tseng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Surgical Oncology, City of Hope National Medical Center, Duarte, California, USA. Hauptthemen laut MEDLINE: Leiomyosarcoma, Vena Cava, Inferior, Vascular Neoplasms, Retroperitoneal Neoplasms. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Leiomyosarcoma Support and Direct Research Foundation.
Abstract (Originalsprache)
Background
In retroperitoneal leiomyosarcoma (RP LMS), the predominant issue is distant metastasis (DM). We sought to determine variables associated with this outcome and disease‐specific death (DSD).
Methods
Data were retrospectively collected on patients with primary RP LMS treated at a high‐volume center from 2002 to 2023. For inferior vena cava (IVC)‐origin tumors, the extent of macroscopic vascular invasion was re‐assessed on each resection specimen and correlated with preoperative cross‐sectional imaging. Crude cumulative incidences were estimated for DM and DSD and univariable and multivariable models were performed.
Results
Among 157 study patients, median tumor size was 11.0 cm and 96.2% of cases were intermediate or high grade. All patients underwent complete resection, 56.7% received chemotherapy (43.9% neoadjuvant) and 14.6% received radiation therapy. Only tumor size and grade and not site of tumor origin (e.g., IVC vs. other) were associated with DM and DSD ( p < 0.05). Among 64 patients with IVC‐origin tumors, a novel 3‐tier classification was devised based on the level of intimal disruption, which was associated with both DM ( p = 0.007) and DSD (0.002).
Conclusion
In primary RP LMS, only tumor size and grade are predictive of DM and DSD. In IVC‐origin tumors, the extent of macroscopic vascular invasion is also strongly predictive of these outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Division of Surgical Oncology, City of Hope National Medical Center, Duarte, California, USA.
- Department of Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Sarcoma Service, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Deparment of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Soft Tissue Tumor Pathology Unit, Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
- Deparment of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
ORCID-Profile: William W Tseng, Marco Baia
Förderung
- Leiomyosarcoma Support and Direct Research Foundation
Zitieren
APA
Tseng, W. W., Barretta, F., Fiore, M., Colombo, C., Radaelli, S., Baia, M., Morosi, C., Collini, P., Sanfilippo, R., Fabbroni, C., Stacchiotti, S., Roberts, R. F., Callegaro, D., & Gronchi, A. (2024). Extent of macroscopic vascular invasion predicts distant metastasis in primary leiomyosarcoma of the inferior vena cava. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27799
Vancouver
Tseng WW, Barretta F, Fiore M, Colombo C, Radaelli S, Baia M, et al. Extent of macroscopic vascular invasion predicts distant metastasis in primary leiomyosarcoma of the inferior vena cava. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27799
BibTeX
@article{Tseng2024,
author = {Tseng, William W and Barretta, Francesco and Fiore, Marco and Colombo, Chiara and Radaelli, Stefano and Baia, Marco and Morosi, Carlo and Collini, Paola and Sanfilippo, Roberta and Fabbroni, Chiara and Stacchiotti, Silvia and Roberts, Randall F and Callegaro, Dario and Gronchi, Alessandro},
title = {Extent of macroscopic vascular invasion predicts distant metastasis in primary leiomyosarcoma of the inferior vena cava},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27799}
}
EUVIMED